share_log

Allogene Therapeutics Analyst Ratings

Allogene Therapeutics Analyst Ratings

Allogene Therapeutic
Benzinga ·  2023/08/07 06:21
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/07/2023 401.09% HC Wainwright & Co. → $23 Reiterates Buy → Buy
08/03/2023 510.02% Oppenheimer → $28 Reiterates Outperform → Outperform
08/03/2023 226.8% EF Hutton → $15 Reiterates Buy → Buy
07/12/2023 292.16% Truist Securities $20 → $18 Maintains Buy
06/26/2023 510.02% Oppenheimer → $28 Assumes → Outperform
06/20/2023 401.09% HC Wainwright & Co. → $23 Reiterates Buy → Buy
06/16/2023 662.53% Canaccord Genuity → $35 Reiterates Buy → Buy
06/05/2023 226.8% JMP Securities → $15 Reiterates → Market Outperform
06/05/2023 226.8% EF Hutton → $15 Reiterates Buy → Buy
05/26/2023 226.8% EF Hutton → $15 Reiterates Buy → Buy
05/05/2023 226.8% JMP Securities $19 → $15 Maintains Outperform
05/05/2023 401.09% HC Wainwright & Co. → $23 Reiterates → Buy
05/04/2023 63.4% Stifel $8 → $7.5 Maintains Hold
05/04/2023 226.8% RBC Capital → $15 Reiterates → Outperform
04/20/2023 401.09% HC Wainwright & Co. → $23 Reiterates → Buy
04/18/2023 313.94% JMP Securities → $19 Reiterates → Market Outperform
04/17/2023 226.8% EF Hutton → $15 Maintains Buy
04/04/2023 401.09% HC Wainwright & Co. $29 → $23 Maintains Buy
03/21/2023 30.72% Bernstein → $6 Initiates Coverage On → Market Perform
03/02/2023 575.38% Goldman Sachs $35 → $31 Maintains Buy
03/02/2023 313.94% JMP Securities $23 → $19 Maintains Market Perform
03/01/2023 379.3% RBC Capital $32 → $22 Maintains Outperform
03/01/2023 510.02% Oppenheimer $32 → $28 Maintains Outperform
03/01/2023 575.38% Goldman Sachs $35 → $31 Maintains Buy
03/01/2023 226.8% EF Hutton → $15 Reiterates → Buy
01/24/2023 139.65% JP Morgan $20 → $11 Upgrades Neutral → Overweight
01/06/2023 161.44% Baird → $12 Upgrades Neutral → Outperform
01/05/2023 226.8% EF Hutton → $15 Initiates Coverage On → Buy
12/12/2022 96.08% B of A Securities → $9 Downgrades Buy → Underperform
11/21/2022 531.81% HC Wainwright & Co. $43 → $29 Maintains Buy
09/22/2022 292.16% B. Riley Securities $21 → $18 Maintains Buy
08/10/2022 662.53% Oppenheimer $40 → $35 Maintains Outperform
08/10/2022 597.17% RBC Capital $35 → $32 Maintains Outperform
08/10/2022 — Raymond James Downgrades Outperform → Market Perform
07/15/2022 597.17% Goldman Sachs $9 → $32 Upgrades Neutral → Buy
06/03/2022 139.65% Baird → $11 Initiates Coverage On → Neutral
05/24/2022 96.08% Goldman Sachs $12 → $9 Maintains Neutral
05/05/2022 183.22% Raymond James $36 → $13 Maintains Outperform
03/07/2022 161.44% Goldman Sachs $20 → $12 Maintains Neutral
12/14/2021 662.53% RBC Capital $45 → $35 Maintains Outperform
10/12/2021 488.24% JMP Securities $53 → $27 Maintains Market Outperform
10/08/2021 — Stifel Downgrades Buy → Hold
10/08/2021 880.39% RBC Capital $55 → $45 Maintains Outperform
10/08/2021 335.73% Goldman Sachs $71 → $20 Downgrades Buy → Neutral
09/24/2021 684.31% Raymond James → $36 Upgrades Market Perform → Outperform
09/23/2021 684.31% Raymond James → $36 Upgrades Market Perform → Outperform
05/20/2021 793.25% Truist Securities $34 → $41 Upgrades Hold → Buy
05/14/2021 1032.9% B. Riley Securities → $52 Initiates Coverage On → Buy
03/01/2021 836.82% HC Wainwright & Co. $40 → $43 Maintains Buy
01/26/2021 836.82% Stifel $33 → $43 Upgrades Hold → Buy
12/10/2020 771.46% HC Wainwright & Co. → $40 Assumes → Buy
10/23/2020 1098.26% RBC Capital → $55 Initiates Coverage On → Outperform
06/12/2020 967.54% HC Wainwright & Co. $55 → $49 Maintains Buy
06/01/2020 1098.26% Oppenheimer $50 → $55 Maintains Outperform
06/01/2020 — Raymond James Downgrades Outperform → Market Perform
05/19/2020 1207.19% Roth Capital → $60 Upgrades Neutral → Buy
05/15/2020 — Guggenheim Upgrades Neutral → Buy
05/14/2020 858.61% Canaccord Genuity $36 → $44 Maintains Buy
05/14/2020 989.32% Oppenheimer $44 → $50 Maintains Outperform
05/14/2020 815.03% HC Wainwright & Co. $35 → $42 Reiterates → Buy
05/14/2020 597.17% SunTrust Robinson Humphrey $29 → $32 Downgrades Buy → Hold
04/13/2020 531.81% SunTrust Robinson Humphrey → $29 Initiates Coverage On → Buy
02/24/2020 488.24% Berenberg → $27 Initiates Coverage On → Hold
12/18/2019 706.1% JMP Securities → $37 Initiates Coverage On → Market Outperform
11/04/2019 684.31% Canaccord Genuity → $36 Initiates Coverage On → Buy
08/09/2019 706.1% BTIG → $37 Initiates Coverage On → Buy
06/05/2019 466.45% Roth Capital → $26 Initiates Coverage On → Neutral
05/31/2019 — Guggenheim Initiates Coverage On → Neutral
05/23/2019 488.24% Stifel → $27 Initiates Coverage On → Hold
05/03/2019 880.39% Oppenheimer → $45 Initiates Coverage On → Outperform
03/29/2019 989.32% Piper Sandler → $50 Initiates Coverage On → Overweight
03/15/2019 771.46% Raymond James → $40 Initiates Coverage On → Outperform
03/14/2019 — William Blair Initiates Coverage On → Outperform
11/05/2018 — Cowen & Co. Initiates Coverage On → Outperform
11/05/2018 531.81% JP Morgan → $29 Initiates Coverage On → Neutral
11/05/2018 575.38% Jefferies → $31 Initiates Coverage On → Buy
11/05/2018 793.25% Goldman Sachs → $41 Initiates Coverage On → Buy
日期 上行/下行 分析公司 目标价格变化 评级变化 上一次/当前评级
08/07/2023 401.09% HC Wainwright公司 →$23 重申 购买→购买
08/03/2023 510.02% 奥本海默 →$28 重申 跑赢→跑赢大盘
08/03/2023 226.8% EF Hutton →$15 重申 购买→购买
07/12/2023 292.16% Truist证券 $20→$18 维护 买
2023/06/26 510.02% 奥本海默 →$28 假设 →跑赢大盘
06/20/2023 401.09% HC Wainwright公司 →$23 重申 购买→购买
06/16/2023 662.53% 卡纳科特·格纳奇 →$35 重申 购买→购买
06/05/2023 226.8% JMP证券 →$15 重申 →市场跑赢大盘
06/05/2023 226.8% EF Hutton →$15 重申 购买→购买
2023年05月26日 226.8% EF Hutton →$15 重申 购买→购买
05/05/2023 226.8% JMP证券 $19→$15 维护 跑赢大盘
05/05/2023 401.09% HC Wainwright公司 →$23 重申 →购买
05/04/2023 63.4% Stifel $8→$7.5 维护 保持
05/04/2023 226.8% 加拿大皇家银行资本 →$15 重申 →跑赢大盘
04/20/2023 401.09% HC Wainwright公司 →$23 重申 →购买
04/18/2023 313.94% JMP证券 →$19 重申 →市场跑赢大盘
04/17/2023 226.8% EF Hutton →$15 维护 买
04/04/2023 401.09% HC Wainwright公司 $29→$23 维护 买
03/21/2023 30.72% 伯恩斯坦 →$6 开始承保 →市场表现
03/02/2023 575.38% 高盛 $35→$31 维护 买
03/02/2023 313.94% JMP证券 $23→$19 维护 市场表现
03/01/2023 379.3% 加拿大皇家银行资本 $32→$22 维护 跑赢大盘
03/01/2023 510.02% 奥本海默 $32→$28 维护 跑赢大盘
03/01/2023 575.38% 高盛 $35→$31 维护 买
03/01/2023 226.8% EF Hutton →$15 重申 →购买
01/24/2023 139.65% 摩根大通 $20→$11 升级 中性→超重
01/06/2023 161.44% 贝尔德 →$12 升级 中性→表现优异
01/05/2023 226.8% EF Hutton →$15 开始承保 →购买
2022年12月12日 96.08% B of A证券 →$9 评级下调 购买表现不佳的→
2022年11月21日 531.81% HC Wainwright公司 $43→$29 维护 买
09/22/2022 292.16% B.莱利证券 $21→$18 维护 买
2022年08月10日 662.53% 奥本海默 $40→$35 维护 跑赢大盘
2022年08月10日 597.17% 加拿大皇家银行资本 $35→$32 维护 跑赢大盘
2022年08月10日 - 雷蒙德·詹姆斯 评级下调 跑赢→市场表现
07/15/2022 597.17% 高盛 $9→$32 升级 中性→购买
06/03/2022 139.65% 贝尔德 →$11 开始承保 →中性
2022年05月24日 96.08% 高盛 $12→$9 维护 中性
05/05/2022 183.22% 雷蒙德·詹姆斯 $36→$13 维护 跑赢大盘
03/07/2022 161.44% 高盛 $20→$12 维护 中性
2021年12月14日 662.53% 加拿大皇家银行资本 $45→$35 维护 跑赢大盘
10/12/2021 488.24% JMP证券 $53→$27 维护 市场表现强于大盘
10/08/2021 - Stifel 评级下调 购买→Hold
10/08/2021 880.39% 加拿大皇家银行资本 $55→$45 维护 跑赢大盘
10/08/2021 335.73% 高盛 $71→$20 评级下调 购买→中性
09/24/2021 684.31% 雷蒙德·詹姆斯 →$36 升级 市场表现优于→
09/23/2021 684.31% 雷蒙德·詹姆斯 →$36 升级 市场表现优于→
05/20/2021 793.25% Truist证券 $34→$41 升级 持有→购买
2021/05/14 1032.9% B.莱利证券 →$52 开始承保 →购买
03/01/2021 836.82% HC Wainwright公司 $40→$43 维护 买
2021/01/26 836.82% Stifel $33→$43 升级 持有→购买
12/10/2020 771.46% HC Wainwright公司 →$40 假设 →购买
10/23/2020 1098.26% 加拿大皇家银行资本 →$55 开始承保 →跑赢大盘
2020/06/12 967.54% HC Wainwright公司 $55→$49 维护 买
06/01/2020 1098.26% 奥本海默 $50→$55 维护 跑赢大盘
06/01/2020 - 雷蒙德·詹姆斯 评级下调 跑赢→市场表现
2020/05/19 1207.19% 罗斯资本 →$60 升级 中性→购买
2020/05/15 - 古根海姆 升级 中性→购买
2020/05/14 858.61% 卡纳科特·格纳奇 $36→$44 维护 买
2020/05/14 989.32% 奥本海默 $44→$50 维护 跑赢大盘
2020/05/14 815.03% HC Wainwright公司 $35→$42 重申 →购买
2020/05/14 597.17% SunTrust Robinson Humphrey $29→$32 评级下调 购买→Hold
04/13/2020 531.81% SunTrust Robinson Humphrey →$29 开始承保 →购买
02/24/2020 488.24% 贝伦伯格 →$27 开始承保 →保留
2019年12月18日 706.1% JMP证券 →$37 开始承保 →市场跑赢大盘
2019/11/04 684.31% 卡纳科特·格纳奇 →$36 开始承保 →购买
2019年08月09日 706.1% BTIG →$37 开始承保 →购买
2019年05月06日 466.45% 罗斯资本 →$26 开始承保 →中性
2019年05月31日 - 古根海姆 开始承保 →中性
2019年05月23日 488.24% Stifel →$27 开始承保 →保留
2019年05月03日 880.39% 奥本海默 →$45 开始承保 →跑赢大盘
2019/03/29 989.32% 派珀·桑德勒 →$50 开始承保 →超重
2019年03月15日 771.46% 雷蒙德·詹姆斯 →$40 开始承保 →跑赢大盘
2019/03/14 - 威廉·布莱尔 开始承保 →跑赢大盘
2018年11月05日 - 考恩公司 开始承保 →跑赢大盘
2018年11月05日 531.81% 摩根大通 →$29 开始承保 →中性
2018年11月05日 575.38% 杰富瑞 →$31 开始承保 →购买
2018年11月05日 793.25% 高盛 →$41 开始承保 →购买

What is the target price for Allogene Therapeutics (ALLO)?

同种异体基因治疗(ALLO)的目标价格是多少？

The latest price target for Allogene Therapeutics (NASDAQ: ALLO) was reported by HC Wainwright & Co. on August 7, 2023. The analyst firm set a price target for $23.00 expecting ALLO to rise to within 12 months (a possible 401.09% upside). 34 analyst firms have reported ratings in the last year.

同种异体基因治疗公司(纳斯达克：ALLO)的最新目标价是由HC Wainwright&Co.于2023年8月7日报道的。这家分析公司将目标价定为2300美元，预计Allo将在12个月内上涨至(可能上涨401.09%)。去年有34家分析公司公布了评级。

What is the most recent analyst rating for Allogene Therapeutics (ALLO)?

同种异体基因治疗公司(Allo)的最新分析师评级是多少？

The latest analyst rating for Allogene Therapeutics (NASDAQ: ALLO) was provided by HC Wainwright & Co., and Allogene Therapeutics reiterated their buy rating.

纳斯达克(代码：ALLO)的最新分析师评级是由HC Wainwright&Co.提供的，Allgene治疗公司重申了他们的买入评级。

When is the next analyst rating going to be posted or updated for Allogene Therapeutics (ALLO)?

异基因治疗公司(Allo)的下一次分析师评级将于何时发布或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Allogene Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Allogene Therapeutics was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.

分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与异种基因治疗公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。异基因治疗公司的上一次评级是在2023年8月7日提交的，所以你应该预计下一次评级将在2024年8月7日左右的某个时候提供。

Is the Analyst Rating Allogene Therapeutics (ALLO) correct?

分析师对同种异体基因治疗公司(Allo)的评级正确吗？

While ratings are subjective and will change, the latest Allogene Therapeutics (ALLO) rating was a reiterated with a price target of $0.00 to $23.00. The current price Allogene Therapeutics (ALLO) is trading at is $4.59, which is within the analyst's predicted range.

虽然评级是主观的，并将发生变化，但最新的异基因治疗(Allo)评级被重申，目标价在0.00美元至23.00美元之间。异基因治疗公司(Allo)目前的交易价格为4.59美元，在分析师的预测范围内。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发